Safety and preliminary efficacy of M9466 (HRS-1167) in combination with abiraterone acetate and prednisone/prednisolone (AA-P) in patients (pts) with metastatic prostate cancer in the phase 1 DDRiver 501 study.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Valentina Boni, Johann S. De Bono, Hiromichi Nakajima, Hiroaki Kikukawa, Sang Joon Shin, Inkeun Park, Shigehisa Kitano, Tatiana Hernandez Guerrero, Irene Moreno, David Olmos, Akira Yokomizo, Sarwan K. Bishnoi, Marta Gil-Martin, Rudi Scheerlinck, Giuseppe Locatelli, Burak Kuersad Guenhan, Andreas Becker, Karin Laaber, Ning Chang, Timothy A. Yap
Institutions: Hospital Universitario Quirónsalud Madrid, Royal Marsden Hospital, National Cancer Center Hospital East, Kumamoto Medical Center, Yonsei University, Yonsei Cancer Hospital, Asan Medical Center, Japanese Foundation For Cancer Research, Delfos Hospital, Hospital Universitario 12 De Octubre, Harasanshin Hospital, Institut Català d'Oncologia, Merck KGaA, Darmstadt (Germany), Merck Healthcare KGaA, Darmstadt (Germany), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162535405
Cites:
Cited by:
Related to: